ArticleMolecular therapy oncolytics2019

A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer.

Sant P Chawla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.